Wilms' tumor gene 1 expression analysis by real-time quantitative polymerase chain reaction for monitoring of minimal residual disease in acute leukemia

2009 ◽  
Vol 50 (8) ◽  
pp. 1326-1332 ◽  
Author(s):  
Alicja Nowakowska-Kopera ◽  
Tomasz Sacha ◽  
Izabela Florek ◽  
Magdalena Zawada ◽  
Sylwia Czekalska ◽  
...  
Keyword(s):  
Polymerase Chain Reaction ◽  
Acute Leukemia ◽  
Minimal Residual Disease ◽  
Residual Disease ◽  
Wilms Tumor ◽  
Quantitative Polymerase Chain Reaction ◽  
Chain Reaction ◽  
Polymerase Chain ◽  
Tumor Gene ◽  
Minimal Residual

scholarly journals Minimal Residual Disease Detection in Acute Lymphoblastic Leukemia

2020 ◽  
Vol 21 (3) ◽  
pp. 1054 ◽  
Author(s):  
Kruse ◽  
Abdel-Azim ◽  
Kim ◽  
Ruan ◽  
Phan ◽  
...  
Keyword(s):  
Polymerase Chain Reaction ◽  
Minimal Residual Disease ◽  
Residual Disease ◽  
Lymphoblastic Leukemia ◽  
Quantitative Polymerase Chain Reaction ◽  
Leukemia Cell ◽  
Chain Reaction ◽  
Phenotypic Marker ◽  
Polymerase Chain ◽  
Minimal Residual

Minimal residual disease (MRD) refers to a chemotherapy/radiotherapy-surviving leukemia cell population that gives rise to relapse of the disease. The detection of MRD is critical for predicting the outcome and for selecting the intensity of further treatment strategies. The development of various new diagnostic platforms, including next-generation sequencing (NGS), has introduced significant advances in the sensitivity of MRD diagnostics. Here, we review current methods to diagnose MRD through phenotypic marker patterns or differential gene patterns through analysis by flow cytometry (FCM), polymerase chain reaction (PCR), real-time quantitative polymerase chain reaction (RQ-PCR), reverse transcription polymerase chain reaction (RT-PCR) or NGS. Future advances in clinical procedures will be molded by practical feasibility and patient needs regarding greater diagnostic sensitivity.

Sign in / Sign up

Export Citation Format

Share Document